Pediatric Cancer

Latest News

Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors

February 16th 2024

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

NCCN Releases Treatment Recommendations for Neuroblastoma
NCCN Releases Treatment Recommendations for Neuroblastoma

February 14th 2024

Artist paint brushes and paint cans of paint over bright watercolor background | Image Credit: © BillionPhotos.com - stock.adobe.com
Creative Art Therapy Lessens Anxiety in Pediatric Patients With Cancer

January 11th 2024

Young female cancer survivor
Most AYA Cancer Survivors Do Not Properly Understand Their Fertility Risks

November 20th 2023

FDA
Entrectinib Is Approved for Pediatric Patients with NTRK+ Solid Tumors

October 21st 2023

Latest CME Events & Activities

Clinical Vignettes: Inaugural International Congress on Pediatric Oncology

View More

Miami Breast 2024: Affiliated CE Symposia

March 7, 2024 - March 10, 2024

View More

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.